依那西普用于成年早发型强直性脊柱炎患者。

Etanercept in adult patients with early onset ankylosing spondylitis.

作者信息

Inman Robert D, Clegg Daniel O, Davis John C, Whitmore James B, Solinger Alan

机构信息

Toronto Western Hospital, Toronto, Ontario, Canada.

出版信息

J Rheumatol. 2006 Aug;33(8):1634-6.

PMID:16881118

Abstract

OBJECTIVE

To determine whether twice-weekly subcutaneous etanercept improves the signs and symptoms of adult patients with early onset ankylosing spondylitis (AS).

METHODS

A retrospective analysis was performed on a subgroup of patients with AS with onset < 18 years of age from a multicenter, double-blind, placebo-controlled, randomized study of etanercept in the treatment of patients with AS. Twenty patients met criteria and are presented.

RESULTS

As early as week four, 5/9 (56%) patients who received etanercept achieved an Assessments in Ankylosing Spondylitis 20% response (ASAS 20) versus only 1/11 (9%) of those who received placebo (p = 0.032). The observed ASAS 20 response continued through week 24, with 6/9 (66%) patients receiving etanercept responding, versus 2/11 of patients receiving placebo (p = 0.025).

CONCLUSION

Etanercept improves signs and symptoms of early onset AS in adult patients for at least 24 weeks.

摘要

目的

确定每周两次皮下注射依那西普是否能改善成年早发型强直性脊柱炎（AS）患者的体征和症状。

方法

对依那西普治疗AS患者的一项多中心、双盲、安慰剂对照、随机研究中发病年龄<18岁的AS患者亚组进行回顾性分析。20例患者符合标准并予以报道。

结果

早在第4周，接受依那西普治疗的9例患者中有5例（56%）达到强直性脊柱炎评估20%反应（ASAS 20），而接受安慰剂治疗的11例患者中只有1例（9%）达到（p = 0.032）。观察到的ASAS 20反应持续至第24周，接受依那西普治疗的9例患者中有6例（66%）有反应，而接受安慰剂治疗的患者中有2例（p = 0.025）。